Please use this identifier to cite or link to this item:
Title: Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network
Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra," Ciudad de México, Mexico
Hospital Universitario Dr. José Eleuterio González. Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Hospital Civil De Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Mexico.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico.
Facultad de Medicina, Universidad de Colima, Colima, Mexico.
Instituto Nacional de Cancerología, Ciudad de México, Mexico.
Hospital General de Zona No. 21 IMSS and Centro Universitario de los Altos (CUALTOS), Universidad de Guadalajara, Tepatitlán De Morelos, Mexico.
Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico.
Universidad de Sonora, Hermosillo, Mexico.
Hospital Ángeles Valle Oriente, San Pedro Garza García, Mexico.
Hospital Infantil de Morelia "Eva Sámano De López Mateos," Morelia, Mexico.
SwissHospital, Monterrey, Mexico.
Hospital General de Zona No.1 IMSS Nueva Frontera, Tapachula, Mexico.
Hospital de Especialidades Pediátricas, Tuxtla Gutiérrez, Mexico.
Hospital General Dr. Agustín O 'Horan, Mérida, Mexico.
Hospital Regional de Alta Especialidad de Oaxaca, San Bartolo Coyotepec, Mexico.
Hospital Regional de Alta Especialidad Bicentenario de la Independencia, Tultitlán de Mariano Escobedo, Mexico.
Hospital para el Niño, Toluca, Mexico.
Hospital Regional de Alta Especialidad del Bajío, León, Mexico.
Sanatorio La Luz, Morelia, Mexico.
Hospital para el Niño Poblano, Puebla, Mexico.
Hospital Dr. Jesús Gilberto Gómez Maza, Tuxtla Gutiérrez, Mexico.
Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico.
Hospital General con especialidades Juan María de Salvatierra, La Paz, Mexico.
Hospital Regional de Delicias, Ciudad Delicias, Mexico.
Hospital Galenia, Cancún, Mexico.
Centro Universitario de Salud UANL, Guadalupe, Mexico.
Hospital Materno Infantil Morelos, Chetumal, Mexico.
Laboratorios Galindo SC, Oaxaca, Mexico.
Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico.
Hospital General Chetumal, Chetumal, Mexico.
Laboratorios del Centro, Zamora, Mexico.
Hospital General Dr. Miguel Silva, Morelia, Mexico.
Análisis Bioquímico Clínicos "Louis Pasteur," Toluca, Mexico.
Escuela Superior de Ciencias Naturales, Universidad Autónoma de Guerrero, Guerrero, Mexico.
Hospital General Dr. Raymundo Abarca Alarcón, Chilpancingo de los Bravo, Mexico.
Hospital de Especialidades Materno Infantil de León, León, Mexico.
Centro Médico Dr. Ignacio Chávez, ISSSTESON, Hermosillo, Mexico.
Hospital General del Estado, Dr. Ernesto Ramos Bours, Hermosillo, Mexico.
Hospital Dr. Fernando Ocarranza, Hermosillo, Mexico.
Centro Integral de Atención a la Salud Sur, ISSSTESON, Hermosillo, Mexico.
Hospital Lic. Adolfo López Mateos, Ciudad Obregón, Mexico.
Hospital General de Ciudad Obregón, Ciudad Obregón, Mexico.
Hospital General de León, León, Mexico.
Hospital de la Madre y el Niño Guerrerense, Chilpancingo de los Bravo, Mexico.
Instituto Nacional de Salud Pública, Cuernavaca, Mexico.
Facultad de Medicina, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Issue Date: Mar-2022
Citation: Microb Drug Resist.2022 Mar;(28)3:338-345
Abstract: Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico. Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic). Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) (p ≤ 0.01) was detected for Staphylococcus aureus, to imipenem (13% vs. 23.4%) and meropenem (11.2% vs. 21.4) (p ≤ 0.01), for Klebsiella pneumoniae. In all specimens, increased ampicillin and tetracycline resistance was detected for Enterococcus faecium (p ≤ 0.01). In cefepime, meropenem, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Escherichia coli; and in piperacillin-tazobactam, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, and gentamicin (p ≤ 0.01), resistance was detected for Pseudomonas aeruginosa. Conclusion: Antimicrobial resistance increased in Mexico during the COVID-19 pandemic. The increase in oxacillin resistance for S. aureus and carbapenem resistance for K. pneumoniae recovered from blood specimens deserves special attention. In addition, an increase in erythromycin resistance in S. aureus was detected, which may be associated with high azithromycin use. In general, for Acinetobacter baumannii and P. aeruginosa, increasing resistance rates were detected.
PMID: 34870473
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:
File Description SizeFormat 
López Jacome_2022_Increment Antimicrobial .pdfLópez Jacome_2022_Increment Antimicrobial2.24 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.